FDA Talking To Industry About Releasing “Complete Response” Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner Hamburg says conversations are underway with industry to allow the agency to release its reasons for not approving a product, in part so others will not waste funds repeating known failures. FDA is also working to remove user fee revenue from sequestration.
You may also be interested in...
Complete Response Letters: Firms See Value In Public Release, Don't Expect It Will Happen
One industry CEO says it would on net be beneficial even though some companies would suffer if they were made public.
Gottlieb Q&A: Confirmation Is Nearing, Will Complete Response Letters Finally Get Released?
Gottlieb favors making the letters detailing application problems public, but industry still may oppose it; Senate schedules cloture vote for confirmation.
Amgen's Reticence On Parsabiv Complete Response Letter Revives Transparency Issue
But Amgen is in good company when it comes to companies that choose not to disclose the contents of complete response letters, data from the Pink Sheet's FDA Performance Tracker show. Merck especially holds such information close.